DLL3 and endometrial carcinoma: The association of DLL3 expression with more aggressive tumor behavior was also found in patients with other high-grade tumor types, such as endometrial carcinoma, lung adenocarcinoma, and small cell bladder cancer (40–42), as well as in SCLC patients (39).